Article

Health-Related Quality of Life in PARP-Inhibitor Olaparib Maintenance in Ovarian Cancer Patients: Real World Data and Experience of a Single-Center in China

2021-08-06

Abstract excerpt

<title>Abstract</title> <p><bold>Objectives:</bold>To preliminarily explore the germline BRCA1/2 gene mutation status of patients with epithelial ovarian cancer (EOC), analyze the relationship with clinicopathological characteristics and the impact on survival and prognosis. Then examine the BRCA1/2 gene sequence mutation rate and the QOL of ovarian cancer patients with oral Olaparib in a single-center of China.<...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 85c6230a-e36b-550a-99e2-98fcfd250f04
DOI: 10.21203/rs.3.rs-751531/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Health-Related Quality of Life in PARP-Inhibitor Olaparib Maintenance in Ovarian Cancer Patients: Real World Data and Experience of a Single-Center in ChinaDOI 10.21203/rs.3.rs-751531/v1Read

Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.Semantic proximity Read

Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohortSemantic proximity Read

Experiencia con el uso de olaparib en pacientes con cáncer de ovario.Semantic proximity Read

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trialSemantic proximity Read

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.Semantic proximity Read

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.Semantic proximity Read

Olaparib and advanced ovarian cancer: Summary of the past and looking into the futureSemantic proximity Read

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Semantic proximity Read

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancerSemantic proximity Read

First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter studySemantic proximity Read

Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.Semantic proximity Read

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.Semantic proximity Read